FDA Enlists FleishmanHillard for $50M Vaccine Awareness Push amid Rising Misinformation

The FDA has tapped FleishmanHillard for a $50 million strategic campaign to combat vaccine misinformation and strengthen public confidence ahead of the 2025 flu season.

The U.S. Food and Drug Administration (FDA) has awarded a $50 million contract to global public relations firm FleishmanHillard to spearhead a national vaccine confidence campaign. The initiative comes as public skepticism surrounding immunizations continues to grow, fueled by misinformation across digital platforms. Targeting the 2025 flu season, the campaign aims to reinforce trust in vaccine safety and efficacy while countering disinformation that has contributed to declining immunization rates. FleishmanHillard is expected to deploy a multi-channel strategy leveraging digital media, community outreach, and targeted messaging to address concerns and promote evidence-based information.

Industry observers see this move as a crucial step in mitigating vaccine hesitancy, particularly as healthcare agencies battle the rapid spread of unverified claims. By partnering with a leading PR firm known for its crisis communication expertise, the FDA is positioning itself to navigate the evolving digital landscape more effectively. The collaboration also underscores a growing trend in public health messaging—aligning with corporate communication specialists to drive behavior change at scale. With advanced data analytics and AI-powered content strategies, FleishmanHillard is set to refine the campaign’s reach, ensuring messaging resonates with key demographics.

This development signals a shift in how federal agencies engage with the public on health matters. The success of this campaign could shape future governmental approaches to combating misinformation, influencing both policy and corporate strategies in the healthcare and pharmaceutical sectors.